Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

BFRI vs PRGO vs MCK vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BFRI
Biofrontera Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$13M
5Y Perf.-98.7%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-74.0%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+261.9%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+287.4%

BFRI vs PRGO vs MCK vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BFRI logoBFRI
PRGO logoPRGO
MCK logoMCK
CAH logoCAH
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - DistributionMedical - Distribution
Market Cap$13M$1.61B$92.15B$43.59B
Revenue (TTM)$42M$4.18B$403.43B$250.55B
Net Income (TTM)$-11M$-1.82B$4.76B$1.56B
Gross Margin75.8%34.2%3.6%3.7%
Operating Margin-27.2%-4.1%1.5%0.9%
Forward P/E5.6x19.3x17.9x
Total Debt$6M$3.97B$7.39B$9.35B
Cash & Equiv.$6M$532M$5.69B$3.87B

BFRI vs PRGO vs MCK vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BFRI
PRGO
MCK
CAH
StockOct 21May 26Return
Biofrontera Inc. (BFRI)1001.3-98.7%
Perrigo Company plc (PRGO)10026.0-74.0%
McKesson Corporation (MCK)100361.9+261.9%
Cardinal Health, In… (CAH)100387.4+287.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: BFRI vs PRGO vs MCK vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. BFRI and CAH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BFRI
Biofrontera Inc.
The Growth Play

BFRI is the clearest fit if your priority is growth exposure.

  • Rev growth 11.8%, EPS growth 100.0%, 3Y rev CAGR 13.3%
  • +62.5% vs PRGO's -51.2%
Best for: growth exposure
PRGO
Perrigo Company plc
The Defensive Pick

PRGO is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.18, current ratio 2.76x
  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.6x vs 17.9x)
  • 9.8% yield, 10-year raise streak, vs CAH's 1.1%, (1 stock pays no dividend)
Best for: sleep-well-at-night and defensive
MCK
McKesson Corporation
The Long-Run Compounder

MCK carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 348.1% 10Y total return vs CAH's 160.8%
  • 16.2% revenue growth vs PRGO's -2.8%
  • 1.2% margin vs PRGO's -43.5%
  • 5.7% ROA vs BFRI's -52.2%, ROIC 5.4% vs -124.3%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Income Pick

CAH is the clearest fit if your priority is income & stability.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Beta 0.03 vs BFRI's 1.67
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs PRGO's -2.8%
ValuePRGO logoPRGOLower P/E (5.6x vs 17.9x)
Quality / MarginsMCK logoMCK1.2% margin vs PRGO's -43.5%
Stability / SafetyCAH logoCAHBeta 0.03 vs BFRI's 1.67
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs CAH's 1.1%, (1 stock pays no dividend)
Momentum (1Y)BFRI logoBFRI+62.5% vs PRGO's -51.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs BFRI's -52.2%, ROIC 5.4% vs -124.3%

BFRI vs PRGO vs MCK vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BFRIBiofrontera Inc.
FY 2023
Government and Payor Rebates
58.2%$310,000
Co-pay Assistance Program
31.0%$165,000
Returns
9.8%$52,000
Prompt Pay Discounts
1.1%$6,000
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

BFRI vs PRGO vs MCK vs CAH — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBFRILAGGINGCAH

Income & Cash Flow (Last 12 Months)

BFRI leads this category, winning 3 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 9673.2x BFRI's $42M. MCK is the more profitable business, keeping 1.2% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, BFRI holds the edge at +36.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBFRI logoBFRIBiofrontera Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$42M$4.2B$403.4B$250.5B
EBITDAEarnings before interest/tax-$11M$58M$6.8B$3.2B
Net IncomeAfter-tax profit-$11M-$1.8B$4.8B$1.6B
Free Cash FlowCash after capex-$13M$108M$6.0B$4.4B
Gross MarginGross profit ÷ Revenue+75.8%+34.2%+3.6%+3.7%
Operating MarginEBIT ÷ Revenue-27.2%-4.1%+1.5%+0.9%
Net MarginNet income ÷ Revenue-25.3%-43.5%+1.2%+0.6%
FCF MarginFCF ÷ Revenue-32.0%+2.6%+1.5%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+36.2%-7.2%+6.0%+11.0%
EPS Growth (YoY)Latest quarter vs prior year+100.0%-56.4%+37.0%-19.5%
BFRI leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 4 of 5 comparable metrics.

At 28.7x trailing earnings, CAH trades at a 2% valuation discount to MCK's 29.2x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than MCK's 18.7x.

MetricBFRI logoBFRIBiofrontera Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Market CapShares × price$13M$1.6B$92.1B$43.6B
Enterprise ValueMkt cap + debt − cash$13M$5.1B$93.8B$49.1B
Trailing P/EPrice ÷ TTM EPS-1.14x29.25x28.72x
Forward P/EPrice ÷ next-FY EPS est.5.56x19.28x17.94x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple7.42x18.74x16.01x
Price / SalesMarket cap ÷ Revenue0.32x0.38x0.26x0.20x
Price / BookPrice ÷ Book value/share0.55x
Price / FCFMarket cap ÷ FCF11.12x17.63x23.56x
PRGO leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-11 for BFRI. BFRI carries lower financial leverage with a 0.59x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs PRGO's 4/9, reflecting solid financial health.

MetricBFRI logoBFRIBiofrontera Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity-11.4%-50.7%+3.0%
ROA (TTM)Return on assets-52.2%-19.8%+5.7%+2.8%
ROICReturn on invested capital-124.3%+3.7%+5.4%+33.8%
ROCEReturn on capital employed-84.8%+4.3%+30.5%+19.2%
Piotroski ScoreFundamental quality 0–94466
Debt / EquityFinancial leverage0.59x1.35x
Net DebtTotal debt minus cash-$231,000$3.4B$1.7B$5.5B
Cash & Equiv.Liquid assets$6M$532M$5.7B$3.9B
Total DebtShort + long-term debt$6M$4.0B$7.4B$9.3B
Interest CoverageEBIT ÷ Interest expense-69.93x-7.20x33.79x6.38x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — BFRI and MCK and CAH each lead in 2 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $129 for BFRI. Over the past 12 months, BFRI leads with a +62.5% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs BFRI's -54.4% — a key indicator of consistent wealth creation.

MetricBFRI logoBFRIBiofrontera Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date+57.2%-13.5%-8.5%-9.5%
1-Year ReturnPast 12 months+62.5%-51.2%+4.6%+22.0%
3-Year ReturnCumulative with dividends-90.5%-58.1%+106.4%+127.3%
5-Year ReturnCumulative with dividends-98.7%-60.1%+286.9%+235.7%
10-Year ReturnCumulative with dividends-98.7%-77.7%+348.1%+160.8%
CAGR (3Y)Annualised 3-year return-54.4%-25.2%+27.3%+31.5%
Evenly matched — BFRI and MCK and CAH each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BFRI and CAH each lead in 1 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than BFRI's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BFRI currently trades 95.8% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBFRI logoBFRIBiofrontera Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5001.67x1.18x0.04x0.03x
52-Week HighHighest price in past year$1.19$28.44$999.00$233.60
52-Week LowLowest price in past year$0.54$9.23$637.00$137.75
% of 52W HighCurrent price vs 52-week peak+95.8%+41.2%+75.3%+79.3%
RSI (14)Momentum oscillator 0–10063.660.916.233.2
Avg Volume (50D)Average daily shares traded122K3.4M757K1.7M
Evenly matched — BFRI and CAH each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and CAH each lead in 1 of 2 comparable metrics.

Analyst consensus: PRGO as "Hold", MCK as "Buy", CAH as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 33.8% for MCK (target: $1007). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricBFRI logoBFRIBiofrontera Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$20.00$1006.50$249.67
# AnalystsCovering analysts363133
Dividend YieldAnnual dividend ÷ price+9.8%+0.4%+1.1%
Dividend StreakConsecutive years of raises101720
Dividend / ShareAnnual DPS$1.15$2.69$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.4%+1.8%
Evenly matched — PRGO and CAH each lead in 1 of 2 comparable metrics.
Key Takeaway

BFRI leads in 1 of 6 categories (Income & Cash Flow). PRGO leads in 1 (Valuation Metrics). 3 tied.

Best OverallBiofrontera Inc. (BFRI)Leads 1 of 6 categories
Loading custom metrics...

BFRI vs PRGO vs MCK vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BFRI or PRGO or MCK or CAH a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BFRI or PRGO or MCK or CAH?

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 28. 7x versus McKesson Corporation at 29. 2x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — BFRI or PRGO or MCK or CAH?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: MCK returned +348. 1% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BFRI or PRGO or MCK or CAH?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Biofrontera Inc. 's 1. 67β — meaning BFRI is approximately 4833% more volatile than CAH relative to the S&P 500. On balance sheet safety, Biofrontera Inc. (BFRI) carries a lower debt/equity ratio of 59% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — BFRI or PRGO or MCK or CAH?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, BFRI leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BFRI or PRGO or MCK or CAH?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -27. 2% for BFRI. At the gross margin level — before operating expenses — BFRI leads at 75. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BFRI or PRGO or MCK or CAH more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — BFRI or PRGO or MCK or CAH?

In this comparison, PRGO (9.

8% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. BFRI does not pay a meaningful dividend and should not be held primarily for income.

09

Is BFRI or PRGO or MCK or CAH better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Biofrontera Inc. (BFRI) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +160. 8%, BFRI: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BFRI and PRGO and MCK and CAH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BFRI is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock. PRGO, CAH pay a dividend while BFRI, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BFRI

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 18%
  • Gross Margin > 45%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BFRI and PRGO and MCK and CAH on the metrics below

Revenue Growth>
%
(BFRI: 36.2% · PRGO: -7.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.